The changes of the immunological indexes in the patients with bone metastases treated with 89SrCl2

Objective: To study the influence of 89SrCl2 on the immunological functions in the patients with bone metastases. Methods: Forty-two patients with proved bone metastases were treated with 89SrCl2 and according to the final therapeutic efficiency for the metastatic lesions, the patients were divided into efficacious and inefficacious group. Twenty untreated healthy adults served as control group. The T lymphocyte subsets CD4+, CD8+, CD4+/CD8+ were analyzed before and after 89SrCl2 treatment. Results: The immunological indexes were not significantly different between the two patient groups before the therapy of 89SrCl2. The indexes between the controls and patients before and after the therapy were different significantly (P<0.05). The indexes of inefficacious patients differed from that of the efficacious patients too (P<0.05). After being treated with 89SrCl2, 37 (88.10%) patients' immunological functions were improved, 33 patients (78.57%) stated that their pain were effectively relieved, 29 (69.05%) patients' bone metastatic lesions reduced. Conclusions: The immunological functions in the patients with bone metastases were inhibited obviously. Treating with 89SrCl2 can improve their immunological functions to a certain extent. The recovery level of the inefficacious patients was lower than that of the efficacious patients. The changes of immunological functions can reflect the therapeutical effectiveness. (authors)